Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Policy And Regulatory Bulletin

This article was originally published in The Pink Sheet Daily

Executive Summary

A regular roundup of stories from our Asia-based editors.

You may also be interested in...



'Sakigake' Treatment Gives Enhertu Rapid Japan OK For Gastric Cancer

Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip

Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy

Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel